{"id":"NCT04711603","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.","officialTitle":"A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-16","primaryCompletion":"2022-01-25","completion":"2022-09-26","firstPosted":"2021-01-15","resultsPosted":"2025-09-10","lastUpdate":"2025-09-10"},"enrollment":178,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Uremic Pruritus"],"interventions":[{"type":"DRUG","name":"MR13A9","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MR13A9/MR13A9","type":"EXPERIMENTAL"},{"label":"Placebo/MR13A9","type":"PLACEBO_COMPARATOR"}],"summary":"Double-blind, Placebo-controlled study to confirm the superiority of MR13A9 to placebo, and followed by extension, open-label treatment to confirm long-term safety of MA13A9 in hemodialysis patients with pruritus.","primaryOutcome":{"measure":"Change From Baseline in the Mean NRS Score at Week 4","timeFrame":"4 weeks","effectByArm":[{"arm":"MR13A9 0.5 Î¼g/kg Group","deltaMin":-2.06,"sd":0.2},{"arm":"Placebo Group","deltaMin":-1.09,"sd":0.2}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["38320524"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":89},"commonTop":["Pyrexia","Diarrhoea","Nasopharyngitis","Vaccination complication","Constipation"]}}